454 related articles for article (PubMed ID: 22367664)
1. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
[TBL] [Abstract][Full Text] [Related]
2. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
[TBL] [Abstract][Full Text] [Related]
3. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder.
Cox DJ; Mikami AY; Cox BS; Coleman MT; Mahmood A; Sood A; Moore M; Burket R; Merkel RL
Arch Pediatr Adolesc Med; 2008 Aug; 162(8):793-4. PubMed ID: 18678816
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
6. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
8. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
11. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
[TBL] [Abstract][Full Text] [Related]
12. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
[TBL] [Abstract][Full Text] [Related]
13. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
14. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
[TBL] [Abstract][Full Text] [Related]
15. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder.
Barkley RA; Murphy KR; O'Connell T; Connor DF
J Safety Res; 2005; 36(2):121-31. PubMed ID: 15896352
[TBL] [Abstract][Full Text] [Related]
16. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
17. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
18. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
Abikoff H; Nissley-Tsiopinis J; Gallagher R; Zambenedetti M; Seyffert M; Boorady R; McCarthy J
J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):166-75. PubMed ID: 19127171
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
20. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial.
Verster JC; Bekker EM; de Roos M; Minova A; Eijken EJ; Kooij JJ; Buitelaar JK; Kenemans JL; Verbaten MN; Olivier B; Volkerts ER
J Psychopharmacol; 2008 May; 22(3):230-7. PubMed ID: 18308788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]